1. 1 Baseline Predictors for One Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration Ying G-S, Maguire MG Ying G-S, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF for the CATT Research Group Available through http://www.med.upenn.edu/cpob/publications_main.shtml http://www.med.upenn.edu/cpob/publications_main.shtml Ying G-S, Maguire MG Ying G-S, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF for the CATT Research Group Available through http://www.med.upenn.edu/cpob/publications_main.shtml http://www.med.upenn.edu/cpob/publications_main.shtml Supported by Cooperative Agreements from the National Eye Institute, National Institutes of Health, DHHS

2. Age 72 69 66 67 Mean VA (SE)Mean VA Change (SE) % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

3. Baseline VA in Study Eye 72 69 66 67 Mean VA (SE) Mean VA Change (SE) % of ≥3-lines Gain 20/X Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

4. Baseline VA in Fellow Eye % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

5. Baseline IOP 72 69 66 67 Mean VA Change (SE) Mean VA (SE) Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

6. Baseline CNV Area 72 69 66 67 Mean VA (SE) Mean VA Change (SE) % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

7. Lesion Type Mean VA (SE) Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

8. RAP Lesion 72 69 66 67 Mean VA Change (SE) % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

9. Baseline Geographic Atrophy Mean VA (SE) Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

10. Baseline Foveal Thickness 72 69 66 67 Mean VA (SE) % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

11. Baseline RPE Elevation 72 69 66 67 Mean VA (SE) Mean VA Change (SE) % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

12. Conclusions Early treatment before VA is profoundly affected will achieve the best VA outcomes 12 Baseline VAVA at 1 YearChange in VA at 1 Year Mean (SE) P-valueMean(SE) P-value <0.0001 <0.0001 20/25 - 20/4076.4 (0.8)3.3 (0.7) 20/50 - 20/8069.2 (0.7)8.4 (0.7) 20/100 – 20/16059.1 (1.0)12.0 (1.0) 20/200 - 20/32041.3 (1.8)7.6 (1.7) Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

13. Conclusions

14. Conclusions Baseline predictors of one year VA outcomes are: Baseline predictors of one year VA outcomes are: Baseline PredictorVA scoreVA Change≥3-lines gain Older Age ↓↓U Worse VA - study eye ↓↑↑ Larger CNV Area ↓↓↓ RPE elevation ↓↓↓ Abnormal IOP ↓↓ > Foveal thickness Inverted U Thin ↓ RAP lesion ↑↑ Any classic ↓ GA ↓ Worse VA - fellow eye ↓ Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129